Clinical Trial Update: An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203 [Phase 3]

View source ↗

Summary

This extension study evaluates the efficacy, safety, and tolerability of BYM338 (bimagrumab) in patients with sporadic inclusion body myositis who previously pa…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sporadic Inclusion Body Myositis

Drugs mentioned

• BYM338 (Bimagrumab) (Bimagrumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Sporadic Inclusion Body Myositis | Phase 3 | Status: COMPLETED | Results posted: 2018-03-13